Table S3. Treatment information in all patients according to years of first diagnosis of breast cancer.

Treatments	n (%)			P
	Patients during 2009−2012 (N=119)	Patients during 2013−2016 (N=475)	Patients during 2017−2020 (N=1,533)
HER2, human epidermal receptor 2; ER, estrogen receptor; PR, progesterone receptor.
Adjuvant chemotherapy	57 (47.9)	226 (47.6)	902 (48.7)	0.821
Adjuvant radiation therapy	85 (71.4)	357 (75.2)	1,410 (76.3)	0.143
Anti-HER2 therapy in HER2-amplified patients	10/11 (90.9)	124/139 (89.2)	518/563 (92.0)	0.279
Endocrine therapy in ER/PR-positive patients	55/67 (82.1)	240/297 (80.8)	919/1,099 (83.6)	0.734